Combating Cancer Stem-Like Cell-Derived Resistance to Anticancer Protein by Liposome-Mediated Acclimatization Strategy
Source abstract
Abstract
Antibody-based therapeutics, which induce apoptosis of malignant cells by selectively binding to their receptors, hold tremendous promise for clinical cancer therapy. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received considerable interest due to its favorable capability of activating apoptosis in cancer cells by interacting with death receptors (DRs). However, cancer stem-like cells (CSCs) show deficient or lower DR and are highly resistant to TRAIL-mediated apoptosis limiting the therapeutic efficacy. Here, we report a liposome-mediated acclimatization strategy to overcome the CSC-emanated TRAIL resistance. The liposomal assemblies coencapsulating plasmid DNA encoding TRAIL and salinomycin enable cancer cells as protein generators to express TRAIL, and more importantly, can acclimatize resistant CSCs to be sensitized to the TRAIL-triggered apoptosis by salinomycin-induced upregulation of DR expression on CSCs. This programmable liposome-based drug codelivery system shows the potential to efficiently eliminate CSCs and inhibit CSC-enriched tumor growth in the orthotopic colon tumor mouse model.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Phagocytosis and Immune Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China
Funding
State Key Laboratory of Natural Medicines · Fok Ying Tong Education Foundation · National Natural Science Foundation of China · Postdoctoral Research Funding of Jiangsu Province · Double First-Rate Discipline Innovation Team
References (50)
Show source-provided references
1. 10.1038/nrd239910.1038/nrd2399 ↗
2. 10.1038/nrd.2017.22710.1038/nrd.2017.227 ↗
3. 10.1016/S0140-6736(20)30262-210.1016/S0140-6736(20)30262-2 ↗
4. 10.1016/S1470-2045(14)70105-610.1016/S1470-2045(14)70105-6 ↗
5. 10.1056/NEJMoa200441310.1056/NEJMoa2004413 ↗
6. 10.1126/science.281.5381.130510.1126/science.281.5381.1305 ↗
7. 10.1038/nrc82110.1038/nrc821 ↗
8. 10.1111/febs.1474210.1111/febs.14742 ↗
9. 10.1007/s10549-008-9924-510.1007/s10549-008-9924-5 ↗
10. 10.1016/j.cllc.2013.12.00510.1016/j.cllc.2013.12.005 ↗
11. 10.1002/cncr.2835310.1002/cncr.28353 ↗
12. 10.1200/JCO.2012.44.105510.1200/JCO.2012.44.1055 ↗
13. 10.3389/fmolb.2021.62833210.3389/fmolb.2021.628332 ↗
14. 10.1038/nrc246510.1038/nrc2465 ↗
15. 10.1038/nrc.2017.2810.1038/nrc.2017.28 ↗
16. 10.1021/nl503565t10.1021/nl503565t ↗
17. 10.3390/pharmaceutics1307106210.3390/pharmaceutics13071062 ↗
18. 10.3390/ijms1808164810.3390/ijms18081648 ↗
19. 10.1056/NEJMra180428010.1056/NEJMra1804280 ↗
20. 10.1038/nm.440910.1038/nm.4409 ↗
21. 10.1016/j.ccr.2012.03.00310.1016/j.ccr.2012.03.003 ↗
22. 10.1021/acs.nanolett.6b0090210.1021/acs.nanolett.6b00902 ↗
23. 10.1038/nrclinonc.2017.4410.1038/nrclinonc.2017.44 ↗
24. 10.1038/s41418-020-0559-310.1038/s41418-020-0559-3 ↗
25. 10.1002/adma.20160309510.1002/adma.201603095 ↗
26. 10.1002/smll.20190299810.1002/smll.201902998 ↗
27. 10.1016/j.cell.2009.06.03410.1016/j.cell.2009.06.034 ↗
28. 10.1038/nchem.277810.1038/nchem.2778 ↗
29. 10.1016/j.biomaterials.2011.09.07210.1016/j.biomaterials.2011.09.072 ↗
30. 10.1080/15592294.2020.178927010.1080/15592294.2020.1789270 ↗
31. 10.3802/jgo.2017.28.e1410.3802/jgo.2017.28.e14 ↗
32. 10.1021/jacs.5b0143510.1021/jacs.5b01435 ↗
33. 10.1007/s12274-020-2954-y10.1007/s12274-020-2954-y ↗
34. 10.1038/ncomms436410.1038/ncomms4364 ↗
35. 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-110.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1 ↗
36. 10.1002/anie.20140026810.1002/anie.201400268 ↗
37. 10.1016/j.biomaterials.2016.06.03010.1016/j.biomaterials.2016.06.030 ↗
38. 10.1002/adfm.20170737110.1002/adfm.201707371 ↗
39. 10.1002/adfm.20130322210.1002/adfm.201303222 ↗
40. 10.1021/acs.nanolett.7b0497610.1021/acs.nanolett.7b04976 ↗
41. 10.1038/s41467-021-21758-410.1038/s41467-021-21758-4 ↗
42. 10.1038/nmat299210.1038/nmat2992 ↗
43. 10.1021/ja309812z10.1021/ja309812z ↗
44. 10.1038/s41565-020-00793-010.1038/s41565-020-00793-0 ↗
45. 10.1021/acs.nanolett.9b0292310.1021/acs.nanolett.9b02923 ↗
46. 10.1073/pnas.130895311110.1073/pnas.1308953111 ↗
47. 10.1016/j.ccr.2013.04.00810.1016/j.ccr.2013.04.008 ↗
48. 10.1016/j.bbrc.2011.08.05410.1016/j.bbrc.2011.08.054 ↗
49. 10.3892/ijo.2013.221510.3892/ijo.2013.2215 ↗
50. 10.1016/j.clcc.2017.01.01110.1016/j.clcc.2017.01.011 ↗